MIB-1 immunohistochemistry in clinical Stage I nonseminomatous testicular germ cell tumors predicts patients at low risk for metastasis

Cancer

Volumn 79, Issue 9, 1997, Pages 1710-1716

  Albers, Peter ^a   Bierhoff, Erhard ^a   Neu, Daniela ^a   Fimmers, Rolf ^a   Wernert, Nicolas ^a   Müller, Stefan C ^a  

^a UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

immunohistochemistry; nonseminomatous testicular germ cell tumor; prognosis; risk factors

Indexed keywords

ALPHA FETOPROTEIN; CHORIONIC GONADOTROPIN BETA SUBUNIT; MONOCLONAL ANTIBODY KI 67;

ARTICLE; CANCER STAGING; CLINICAL FEATURE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; METASTASIS; NON SEMINOMATOUS GERMINOMA; ORCHIECTOMY; PRIORITY JOURNAL; PROGNOSIS; RADIODIAGNOSIS; RETROSPECTIVE STUDY; RISK FACTOR;

ANTIBODIES, MONOCLONAL; GERMINOMA; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MALE; MULTIVARIATE ANALYSIS; NEOPLASM METASTASIS; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; RECEPTORS, ANTIGEN; REPRODUCIBILITY OF RESULTS; RISK FACTORS; TESTICULAR NEOPLASMS;

EID: 0030977823     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19970501)79:9<1710::AID-CNCR11>3.0.CO;2-0     Document Type: Article

References (24)

1. Donohue JP, Thornhill JA, Foster RS, Rowland RG, Bihrle R. Primary retroperitoneal lymph node dissection in clinical stage A nonseminomatous germ cell testis cancer. Br J Urol 1993; 71:326-35.
2. Read G, Stenning SP, Cullen MH, Parkinson MC, Horwich A, Kaye SB, et al. Medical Research Council prospective study of surveillance for stage I testicular teratoma. J Clin Oncol 1992; 10:1762-8.
3. Peckham MJ, Barrett A, Husband JE, Hendry WF. Orchidectomy alone in testicular stage I non-seminomatous germ cell tumours. Lancet 1982; 11:678-80.
4. Freedman LS, Parkinson MC, Jones WG, Oliver RTD, Peckham MJ, Read G, et al. Histopathology in the prediction of relapse of patients with stage I testicular teratoma treated by orchiectomy alone. Lancet 1987; 11:294-8.
5. Klepp O, Olsson AM, Henrikson H, Aass N, Dahl O, Stenwig AE, et al. Prognostic factors in clinical stage I nonseminomatous germ cell tumors of the testis: multivariate analysis of a prospective multicenter study. J Clin Oncol 1990; 8:509-18.
6. Pont J, Hoeltl W, Kosak D, Machacek E, Kienzer H, Julcher H, et al. Risk-adapted treatment choice in stage I nonseminomatous testicular germ cell cancer by regarding vascular invasion in the primary tumor: a prospective trial. J Clin Oncol 1990; 8:16-20.
7. McLeod DG, Weiss RB, Stablein DM, Muggia FM, Paulson DF, Ellis JH, et al. Staging relationships and outcome in early stage testicular cancer: a report from the Testicular Cancer Intergroup Study. J Urol 1991; 145:1178-83.
8. Hoeltl W, Pont J, Kosak D, Honetz N, Marberger M. Treatment decision for stage I nonseminomatous germ cell tumours based on the risk factor "vascular invasion." Br J Urol 1992; 69:83-7.
9. Oliver RTD, Raja MA, Ong J, Gallagher CJ. Pilot study to evaluate impact of a policy of adjuvant chemotherapy for high risk stage I malignant teratoma on overall relapse rate of stage I cancer patients. J Urol 1992; 148:1453-6.
10. Moul JW, McCarthy WF, Fernandez EB, Sesterhenn IA. Percentage of embryonal carcinoma and of vascular invasion predicts pathological stage in clinical stage I nonseminomatous testicular cancer. Cancer Res 1994; 54:362-4.
11. Allhoff EP, Liedke S, Wittekind C, deRiese W, Lenis G, Tanke H, et al. DNA-content in NSGCT/CS I: a new prognosticator for biologie behaviour. J Cancer Res Clin Oncol 1990; 1(Suppl):592.
12. Fosså SD, Nesland JM, Waehre H, Åmellem Ø, Petterson EO. DNA ploidy in the primary tumor from patients with nonseminomatous testicular germ cell tumors clinical stage I. Cancer 1991; 67:1874-7.
13. de Riese WTW, de Riese C, Ulbright TM, Walker EB, Messemer J, Jones JA, et al. Flow-cytometric and quantitative histologic parameters as prognostic indicators for occult retroperitoneal disease in clinical-stage-I non-seminomatous testicular germ-cell tumors. Int J Cancer 1994; 57:628-33.
14. de Riese WT, Albers P, Walker EB, Ulbright TM, Crabtree WN, Reister T, et al. Predictive parameters of biologic behavior of early stage nonseminomatous testicular germ cell tumors. Cancer 1994; 74:1335-41.
15. Moul JW, Foley JP, Hitchcock CL, McCarthy WF, Sesterhenn IA, Becker RL, et al. Flow cytometry and quantitative histological parameters to predict occult disease in clinical stage I nonseminomatous testicular germ cell tumors. J Urol 1993; 150:879-83.
16. AJbers P, Miller GA, Orazi A, Ulbright TM, Albers J, Donohue JP, et al. Immunohistochemical assessment of tumor proliferation and volume of embryonal carcinoma identify clinical stage A non-seminomatous testicular germ cell tumor patients at low risk for occult metastasis. Cancer 1995; 75:844-50.
17. Albers P, Ulbright TM, Albers J, Miller GA, Orazi A, Crabtree WN, et al. Tumor proliferative activity is predictive of pathological stage in clinical stage A non-seminomatous testicular germ cell tumors. J Urol 1996; 155:579-86.
18. Cattoretti G, Becker MHG, Key G, Duchrow M, Schlüter C, Galle J, et al. Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB-1 and M1B-3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections. J Pathol 1992; 168:357-63.
19. Albers P, de Riese WT, Ulbright TM, Donohue JP, Foster RS. Prognostic factors in patients with pathological stage I nonseminomatous testicular germ cell tumors and tumor recurrence during follow-up. Urol Res 1995; 23:211-3.
20. Fearon ER, Vogelstein BA. A genetic model of colorectal tumorigenesis. Cell 1990; 61:759-61.
21. Chang F, Syrjänen S, Syrjänen K. Implications of the p53 tumor-suppressor gene in clinical oncology. J Clin Oncol 1995; 13:1009-22.
22. Liotta LA. Steeg PS, Stetler-Stevenson WG. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 1991; 64:327-36.
23. Leibovitch I, Foster RS, Donohue JP. Adult primary pure teratoma of the testis: the Indiana experience. Cancer 1995; 75:2244-50.
24. Kratzik C, Hoeltl W, Albrecht W, Pont J, Breindl E, Pummer K, et al. Risk-adapted management of clinical stage I NSGCT-long-term results of a multicenter trial. Urologe A 1995a;34(Suppl):S113.